Evidence map›Paper›PMID 31157568›Full record

ArticleDiabetes technology & therapeutics2019

Development and Validation of PREDICT-DM: A New Microsimulation Model to Project and Evaluate Complications and Treatments of Type 2 Diabetes Mellitus.

Pooyan Kazemian, Deborah J Wexler, Naomi F Fields, Robert A Parker, Amy Zheng, Rochelle P Walensky

Open access · bronzeAbstract readValidation Study
In one paragraph

Article in Diabetes technology & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Observational
  5. Review
  6. Article
  7. Modeling Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022
    Review
  8. Economic Simulation Modeling in Type 2 Diabetes.Current diabetes reports · 2020
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Pooyan Kazemian1 Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts.
Deborah J Wexler3 Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Naomi F Fields1 Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts.
Robert A Parker1 Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts.
Amy Zheng3 Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Rochelle P Walensky1 Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts.
Harvard University · USMassachusetts General Hospital · US

Funding

Transgenic CoreP30DK057521 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI FLOREZ, JOSE CARLOS · 2000 to 2019
$31.4M
NIDDK NIH HHS P30 DK057521
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes Mellitus, Type 2Models, StatisticalCohort StudiesComputer SimulationForecastingHumansOutcome Assessment, Health CareRandomized Controlled Trials as TopicReproducibility of ResultsRisk FactorsUnited StatesDiabetesModelPREDICT-DMPredictionSimulationValidation

Identifiers

PMID31157568
PMCPMC6551972
OpenAlexW2948798863

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.